{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-338013","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2026-08-06T20:11:08+00:00","discovered_at":"2026-08-06T20:12:01.655740+00:00","generated_at":"2026-08-06T20:15:07.076658+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Relay Therapeutics Q2 2026 net loss $83.7M; cash $910.9M; selected zovegalisib triplet for 1L breast cancer","bullets":["Net loss $83.7M ($0.41/sh) vs $70.4M ($0.41/sh) in Q2 2025; R&D expenses rose to $76.5M.","Cash $910.9M at June 30, 2026, up from $642.1M at March 31, 2026, after $316M follow-on offering in May 2026.","Selected zovegalisib + atirmociclib + endocrine therapy as 1L breast cancer triplet; Phase 3 trial expected early 2027.","Initial ReInspire data: 60% volumetric response at 12 weeks in vascular anomalies; expansion cohorts opened.","ATM offering capacity increased to $462.978M; $162.978M already sold under prior $250M program."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-338013","json":"https://secwatch.observer/filing/0001193125-26-338013.json","markdown":"https://secwatch.observer/filing/0001193125-26-338013.md","text":"https://secwatch.observer/filing/0001193125-26-338013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000119312526338013/0001193125-26-338013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000119312526338013/rlay-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:15:07.076658+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}